Innovax

Focus: Innovax is a Chinese biotechnology company specializing in recombinant vaccine development using E. coli technology, with a focused pipeline in HPV and hepatitis E vaccines. Founded in 2022 and based in Haicang District, the company is early-stage with limited public scale data.

Infectious Diseases Vaccines

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Innovax

AI assessmentNot Hiring

No open roles listed right now. Follow Innovax to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

8 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Scientific videos

HPV Vaccination Rates

N/A

Clinical Trials (1)

NCT07525245Effectiveness of Large Language Model-Based Chatbot Among Parents of Junior High School Girls in Improving Human Papillomavirus (HPV) Vaccine Awareness, Intention and Vaccination Rates

N/A

Help build intelligence for Innovax

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to work on high-impact vaccines addressing cervical cancer and hepatitis E in an underserved market
Ground-floor position at a newly founded biotech (2022) with multiple programs in Phase 3/4 clinical development
Specialized expertise in recombinant E. coli vaccine technology differentiates the platform from competitors

Watch Out For

Extreme opacity: no revenue, employee count, funding data, or recent news published, creating uncertainty about financial stability and runway
Minimal hiring signal (1 active role in sales) suggests either early-stage constraints or limited growth capacity
China-based headquarters may present regulatory, geopolitical, or market access risks relative to US/EU-domiciled peers

Generated by Claude from Innovax's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

Clinical Trials (1)

NCT04969445The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

N/A

A Post-marketing Observational Database Study Monitoring the Safety of CecolinⓇ

Autoimmune Diseases

N/A

Clinical Trials (1)

NCT06824896A Post-marketing Observational Database Study Monitoring the Safety of CecolinⓇ

N/A

3 doses of HPV 16/18 bivalent vaccine

Cervical Intraepithelial Neoplasia

N/A

Clinical Trials (1)

NCT03206255Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

Clinical Trials (1)

NCT06243666Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

Clinical Trials (1)

NCT04704908Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

N/A

Recombinant Human Papillomavirus Nonavalent

Cervical Cancer

N/A

Clinical Trials (1)

NCT06197802Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

N/A

Recombinant Human Papillomavirus Bivalent

Cervical Intraepithelial Neoplasia

N/A

Clinical Trials (1)

NCT05045755The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female

N/A

HPV Vaccine,135μg/0.5ml

Condylomata Acuminata

Phase 1

Clinical Trials (1)

NCT03813940Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Phase 1

HPV 16/18

Cervical Cancer

Phase 1

Clinical Trials (1)

NCT01263327Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Phase 1

low dosage HPV Vaccine

Condylomata Acuminata

Phase 1

Clinical Trials (1)

NCT02405520Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

Phase 1

Hecolin® Recombinant Hepatitis E Vaccine

Hepatitis E Virus Infection

Phase 2

Clinical Trials (1)

NCT06306196Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children

Phase 2

low dosage HPV Vaccine

Condylomata Acuminata

Phase 2

Clinical Trials (1)

NCT02710851Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine

Phase 2

HPV Vaccine,270μg/1.0ml

Condylomata Acuminata

Phase 2

Clinical Trials (1)

NCT03935204Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Phase 2

30μg HPV

Cervical Intraepithelial Neoplasia

Phase 2

Clinical Trials (1)

NCT01356823Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine

Phase 2

3 doses of HPV 16/18 bivalent vaccine

Cervical Intraepithelial Neoplasia

Phase 3

Clinical Trials (1)

NCT02562508A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls

Phase 3

Recombinant Human Papillomavirus Nonavalent

Cervical Cancer

Phase 3

Clinical Trials (1)

NCT04782895Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

Phase 3

3 doses of the Recombinant Human Papillomavirus Nonavalent

Cervical Cancer

Phase 3

Clinical Trials (1)

NCT05056402An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old

Phase 3

Recombinant Human Papillomavirus 9-Valent

Penile/Perineal /Perianal Intraepithelial Neoplasia

Phase 3

Clinical Trials (1)

NCT06866574A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males

Phase 3

HPV Vaccine

Cervical Intraepithelial Neoplasia

Phase 3

Clinical Trials (1)

NCT01735006Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine

Phase 3

Nonavalent HPV vaccine

Cervical Intraepithelial Neoplasia

Phase 3

Clinical Trials (1)

NCT04537156Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)